Originally published as JCO Early Release 10.1200/JCO.2005.05.4882 on July 5 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perez, E. A. Articles by Goss, P. E. Search for Related Content PubMed PubMed Citation Articles by Perez, E. A. Articles by Goss, P. E. Related Articles Related Correspondence Social Bookmarking                            What's this?

Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17

Edith A. Perez, Robert G. Josse, Kathleen I. Pritchard, James N. Ingle, Silvana Martino, Brian P. Findlay, Tamara N. Shenkier, Richard G. Tozer, Michael J. Palmer, Lois E. Shepherd, Shifang Liu, Dongsheng Tu, Paul E. Goss

From the St Michael's Hospital; Toronto Sunnybrook Regional Cancer Centre, Toronto; Hotel Dieu Health Sciences Hospital, St Catharines; Juravinski Cancer Centre, Hamilton; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario; British Columbia Cancer Agency, Vancouver Cancer Clinic, Vancouver, British Columbia, Canada; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Cancer Institute Medical Group, Santa Monica, CA; and Massachusetts General Hospital, Boston, MA

Address reprint requests to Edith A. Perez, MD, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224; e-mail: perez.edith{at}mayo.edu

PURPOSE: Aromatase inhibition depletes estrogen levels and may be associated with accelerated bone resorption. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study MA.17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen.

PATIENTS AND METHODS: Eligible women had a baseline BMD T score of at least 2.0 in either the hip or L2-4 spine; all received calcium 500 mg and vitamin D 400 U daily. Percentage change in BMD (L2-L4 spine and hip) at 12 and 24 months, rate of osteoporosis, and change in markers of bone formation (serum bone alkaline phosphatase) and resorption (serum C-telopeptide and urine N-telopeptide) at 6, 12, and 24 months were compared.

RESULTS: Two hundred twenty-six patients (122 letrozole, 104 placebo) were enrolled. Baseline characteristics were similar in the two groups, including BMD, median age of 60.7 years (81% < 70 years), and median follow-up of 1.6 years. At 24 months, patients receiving letrozole had a significant decrease in total hip BMD (–3.6% v –0.71%; P = .044) and lumbar spine BMD (–5.35% v –0.70%; P = .008). Letrozole increased urine N-telopeptide at 6, 12, and 24 months (P = .054, < .001, and .016, respectively). No patient went below the threshold for osteoporosis in total hip BMD, whereas at the L2-L4 (posteroanterior view), more women became osteoporotic by BMD while receiving letrozole (4.1% v 0%; P = .064).

CONCLUSION: After 5 years of adjuvant tamoxifen, subsequent letrozole causes a modest increase in bone resorption and reduction in bone mineral density in the spine and hip compared to placebo. Further follow-up is necessary to evaluate the long-term clinical implications of this difference.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Changes in Bone Mineral Density After Adjuvant Aromatase Inhibitors and Fracture Risk in Breast Cancer Patients
  Alfredo Berruti, Marcello Tucci, Alessandra Mosca, Federica Vana, Mara Ardine, Luigi Dogliotti, Alberto Angeli, and Francesco Bertoldo
  JCO 2007 25: 1455-1456 [Full Text]

This article has been cited by other articles:

				M. Rabaglio, Z. Sun, K. N. Price, M. Castiglione-Gertsch, H. Hawle, B. Thurlimann, H. Mouridsen, M. Campone, J. F. Forbes, R. J. Paridaens, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann. Onc., September 1, 2009; 20(9): 1489 - 1498. [Abstract] [Full Text] [PDF]

				G. B. Mann, Y. C. Kang, C. Brand, P. R. Ebeling, and J. A. Miller Secondary Causes of Low Bone Mass in Patients With Breast Cancer: A Need for Greater Vigilance J. Clin. Oncol., August 1, 2009; 27(22): 3605 - 3610. [Abstract] [Full Text] [PDF]

				P. M. Camacho, A. S. Dayal, J. L. Diaz, F. A. Nabhan, M. Agarwal, J. G. Norton, P. A. Robinson, and K. S. Albain Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis J. Clin. Oncol., November 20, 2008; 26(33): 5380 - 5385. [Abstract] [Full Text] [PDF]

				F. Saad, J. D. Adachi, J. P. Brown, L. A. Canning, K. A. Gelmon, R. G. Josse, and K. I. Pritchard Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer J. Clin. Oncol., November 20, 2008; 26(33): 5465 - 5476. [Abstract] [Full Text] [PDF]

				P. E. Lonning Endocrine Therapy and Bone Loss in Breast Cancer: Time to Close in the RANK(L)? J. Clin. Oncol., October 20, 2008; 26(30): 4859 - 4861. [Full Text] [PDF]

				T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa Ten-Year Follow-Up of 3 Years of Oral Adjuvant Clodronate Therapy Shows Significant Prevention of Osteoporosis in Early-Stage Breast Cancer J. Clin. Oncol., September 10, 2008; 26(26): 4289 - 4295. [Abstract] [Full Text] [PDF]

				K. Gibson and C. L O'Bryant Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 139 - 145. [Abstract] [PDF]

				P. Hadji, J. -J. Body, M. S. Aapro, A. Brufsky, R. E. Coleman, T. Guise, A. Lipton, and M. Tubiana-Hulin Practical guidance for the management of aromatase inhibitor-associated bone loss Ann. Onc., August 1, 2008; 19(8): 1407 - 1416. [Abstract] [Full Text] [PDF]

				J. N. Ingle, D. Tu, J. L. Pater, H. B. Muss, S. Martino, N. J. Robert, M. J. Piccart, M. Castiglione, L. E. Shepherd, K. I. Pritchard, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 Ann. Onc., May 1, 2008; 19(5): 877 - 882. [Abstract] [Full Text] [PDF]

				P. E. Goss, J. N. Ingle, J. L. Pater, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, L. E. Shepherd, K. I. Pritchard, et al. Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen J. Clin. Oncol., April 20, 2008; 26(12): 1948 - 1955. [Abstract] [Full Text] [PDF]

				D. Crivellari, Z. Sun, A. S. Coates, K. N. Price, B. Thurlimann, H. Mouridsen, L. Mauriac, J. F. Forbes, R. J. Paridaens, M. Castiglione-Gertsch, et al. Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial J. Clin. Oncol., April 20, 2008; 26(12): 1972 - 1979. [Abstract] [Full Text] [PDF]

				M. Rudas, M. Lehnert, A. Huynh, R. Jakesz, C. Singer, S. Lax, W. Schippinger, O. Dietze, R. Greil, W. Stiglbauer, et al. Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy Clin. Cancer Res., March 15, 2008; 14(6): 1767 - 1774. [Abstract] [Full Text] [PDF]

				P Hadji Menopausal symptoms and adjuvant therapy-associated adverse events Endocr. Relat. Cancer, March 1, 2008; 15(1): 73 - 90. [Abstract] [Full Text] [PDF]

				R. Eastell, J. E. Adams, R. E. Coleman, A. Howell, R. A. Hannon, J. Cuzick, J. R. Mackey, M. W. Beckmann, and G. Clack Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230 J. Clin. Oncol., March 1, 2008; 26(7): 1051 - 1057. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Advances in Adjuvant Endocrine Therapy for Postmenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805. [Abstract] [Full Text] [PDF]

				A. M. Brufsky Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives Oncologist, February 1, 2008; 13(2): 187 - 195. [Abstract] [Full Text] [PDF]

				S. Aebi and M. Rabaglio Overview of Current Approaches to Adjuvant Endocrine Therapy ASCO Educational Book, January 1, 2008; 2008(1): 9 - 13. [Abstract] [Full Text] [PDF]

				E. A. Ariazi, A. Leitao, T. I. Oprea, B. Chen, T. Louis, A. M. Bertucci, C. G.N. Sharma, S. D. Gill, H. R. Kim, H. A. Shupp, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen Mol. Cancer Ther., November 1, 2007; 6(11): 2817 - 2827. [Abstract] [Full Text] [PDF]

				A. Berruti, M. Tucci, A. Mosca, F. Vana, M. Ardine, L. Dogliotti, A. Angeli, and F. Bertoldo Changes in Bone Mineral Density After Adjuvant Aromatase Inhibitors and Fracture Risk in Breast Cancer Patients J. Clin. Oncol., April 10, 2007; 25(11): 1455 - 1456. [Full Text] [PDF]

				A. J. Chien and P. E. Goss Aromatase Inhibitors and Bone Health in Women With Breast Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5305 - 5312. [Full Text] [PDF]

				T. A. Guise Bone Loss and Fracture Risk Associated with Cancer Therapy Oncologist, November 1, 2006; 11(10): 1121 - 1131. [Abstract] [Full Text] [PDF]